Get the Stockscreener App
1.33
2.31%
0.03
After Hours:
1.34
0.01
+0.75%
Alector Inc stock is traded at $1.33, with a volume of 482.34K.
It is up +2.31% in the last 24 hours and down -27.32% over the past month.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
See More
Previous Close:
$1.30
Open:
$1.3
24h Volume:
482.34K
Relative Volume:
0.57
Market Cap:
$131.78M
Revenue:
$97.06M
Net Income/Loss:
$-130.39M
P/E Ratio:
-0.8581
EPS:
-1.55
Net Cash Flow:
$-186.54M
1W Performance:
-11.92%
1M Performance:
-27.32%
6M Performance:
-78.34%
1Y Performance:
-78.55%
1-Day Range:
$1.28
$1.35
1-Week Range:
$1.28
$1.57
52-Week Range:
$1.28
$6.78
Alector Inc Stock (ALEC) Company Profile
Name
Alector Inc
Sector
Industry
Phone
415-231-5660
Address
131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO
Compare ALEC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALEC
Alector Inc
|
1.33 | 131.78M | 97.06M | -130.39M | -186.54M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Alector Inc Stock (ALEC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Downgrade | Mizuho | Outperform → Neutral |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-04-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-29-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-26-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-14-23 | Upgrade | Stifel | Hold → Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Sep-25-23 | Initiated | Goldman | Sell |
| Sep-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-13-22 | Initiated | Goldman | Sell |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Sep-27-21 | Initiated | William Blair | Outperform |
| Jan-15-21 | Resumed | BofA Securities | Buy |
| Jun-24-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Goldman | Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-19-20 | Initiated | Stifel | Buy |
| Nov-21-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | Barclays | Overweight |
| Mar-04-19 | Initiated | BofA/Merrill | Buy |
| Mar-04-19 | Initiated | Morgan Stanley | Overweight |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
View All
Alector Inc Stock (ALEC) Latest News
Alector stock hits 52-week low at $1.29 amid sharp annual decline - Investing.com Australia
Alector at Virtual CNS Forum: Advancing Neurodegenerative Treatments By Investing.com - Investing.com South Africa
Alector at Virtual CNS Forum: Advancing Neurodegenerative Treatments - Investing.com
Alector: Q4 Of 2025 FTD-GRN Treatment Data Is Important Inflection Point (NASDAQ:ALEC) - Seeking Alpha
Mizuho’s latest rating for ALEC stock - Knox Daily
Alector at Leerink Global Healthcare Conference: Strategic Advances in Neurodegeneration - Investing.com India
Alector announces workforce reduction to cut costs By Investing.com - Investing.com Australia
Alector announces workforce reduction to cut costs - Investing.com
Alector to Cut 13% of Workforce - MarketWatch
Have Alector Insiders Been Selling Stock? - Simply Wall St
Alector, Inc. (NASDAQ:ALEC) Receives $3.75 Consensus Target Price from Analysts - Defense World
Alector assumed with an Underweight at Morgan Stanley - TipRanks
Alector at TD Cowen Conference: Advancing Neurodegenerative Therapies - Investing.com India
Alector at TD Cowen Conference: Advancing Neurodegenerative Therapies By Investing.com - Investing.com UK
Alector Executives Sell Shares to Satisfy Tax Obligations - TradingView
Top Alector Executives Cash In on Massive Stock Sales! - TipRanks
Alector stock hits 52-week low at $1.54 amid sharp annual decline - Investing.com Australia
Alector stock hits 52-week low at $1.54 amid sharp annual decline By Investing.com - Investing.com South Africa
Research Analysts Set Expectations for Alector Q1 Earnings - Defense World
Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St
Alector (NASDAQ:ALEC) Receives "Buy" Rating from HC Wainwright - MarketBeat
Alector Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Alector’s Earnings Call: Progress Amid Challenges - TipRanks
Alector (NASDAQ:ALEC) Releases Earnings Results, Beats Expectations By $0.59 EPS - MarketBeat
Alector Inc (ALEC) Shares Up Despite Recent Market Volatility - The News Heater
Alector, Inc. (NASDAQ:ALEC) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Alector Inc Q4 2024 sees cautious market reaction By Investing.com - Investing.com South Africa
Alector Inc (ALEC) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising Clinical Advances - GuruFocus.com
Alector: Q4 Earnings Snapshot - mySA
The Bold Bet on Brain Health: Alector’s Race Against Time in Neurodegenerative Research - Smartphone Magazine
Alector Inc (NASDAQ:ALEC): The Biotech Pioneering New Frontiers in Neurodegenerative Diseases - Jomfruland.net
Alector beats Q4 estimates, shares edge higher By Investing.com - Investing.com South Africa
Alector Inc (ALEC) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ... - Yahoo Finance
Alector, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Alector’s 2024 Financial Results and Clinical Advancements - TipRanks
Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings call transcript: Alector Inc Q4 2024 sees cautious market reaction - Investing.com
Alector beats Q4 estimates, shares edge higher - Investing.com India
Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Alector, Inc. SEC 10-K Report - TradingView
Alector, Inc. Reports Q4 2024 Financial Results and Provides Updates on Clinical Trials and Pipeline Development - Nasdaq
Can Alector's $413M Cash Position Fuel Its Alzheimer's Breakthrough? Q4 Results Reveal Strategy - StockTitan
Alector Inc Stock (ALEC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):